article

Drug Target Review – Issue 3 2020

Posted: 8 September 2020 | | No comments yet

This issue includes articles that explore how a next-generation genomics platform can be used for COVID-19 research, the elimination of neutralising AAV antibodies for gene therapies and a new quick and cost-effective biomarker technology for cancer diagnostics. Also in this issue are features on antibody therapeutics for COVID-19 and targets to control M. tuberculosis

DTR - Issue 3 2020

This issue includes:

  • ANTIBODIES
    Oncology meets immunology – antibody-mediated regulation of the immune response
    Aparajita Dubey, CRAMbridge
  • TARGETS
    Exploring the intra-protein non-covalent interactions in the S1 domain of the SARS-CoV-2 S1 Spike protein
    Oscar Bastidas, University of Minnesota
  • FLOW CYTOMETRY
    Flow cytometry in neglected tropical diseases – a focus on leishmaniasis
    Professor Paul Kaye, University of York
  • ASSAYS
    Exploring new drug targets in Alzheimer’s disease
    Monika Schmidt, University of Hradec Kralove
    Sheraz Gul, Fraunhofer Institute
  • NGS
    NGS: offering a glimmer of hope in the fight against COVID-19
    Pushpanathan Muthuirulan, Harvard University
  • CNS/NEUROSCIENCE
    Cocaine and the brain: identifying targets for addiction therapies
    Hannah Balfour, Drug Target Review
  • SYNTHETIC BIOLOGY 
    Understanding the limits of synthetic biology through the origins of SARS-CoV-2
    Marc Baiget Francesch, International Journal of Molecular Sciences

The rest of this content is restricted - login or subscribe free to access

Screening the future innovations in drug discoveryThank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • quarterly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here